Lilly's $3.8 Billion Vaccine Bets: A Quiet Shift Now
Lilly's heavy reliance on GLP-1 drugs has investors watching as the company bets $3.8B on vaccines. This analysis exp...
When index levels rise, adjust allocations gradually and monitor sectors leading the move. This intro provides simple steps to respond without overreacting.
19,220 articlesLilly's heavy reliance on GLP-1 drugs has investors watching as the company bets $3.8B on vaccines. This analysis exp...
Emerging frontier AI models are changing how we spot flaws in crypto systems. This in-depth look explains what fronti...
Goldman Sachs expands its US Conviction List with four new names pegged for double-digit upside, signaling a continue...
Anthropic’s Boris Cherny says he oversees a growing fleet of AI agents, signaling a dramatic shift in software develo...
A 66-year-old retiree with $94,000 pension learns that Medicare IRMAA surcharges can push monthly premiums higher, ev...
When a top executive sells a chunk of stock, it draws attention. This guide examines brian chesky just sold, what ins...
Santiment flags extreme fear in Ethereum social sentiment as retail turns cautious. On-chain signals imply a countert...
Figure Technology Solutions is acquiring Kiavi in a $717 million deal, expanding its first-lien lending and investor-...
A harsh week for AI chips created real bargains. This article identifies three beaten-down chip stocks worth a closer...
Oracle reports a surge in cloud revenue and record backlog, but shares drift. Market talk centers on whether AI infra...
Adobe prepares to report Q2 results after the bell as investors scrutinize AI-driven growth, ARR expansion, and capit...
Oracle stock faces a pivotal moment as management doubles down on AI infrastructure while financing plans raise dilut...